Notably, before the approval of IL-6 blockers, TNF antagonists were administered more frequently in patients with sJIA and, to a lesser extent, in patients with AOSD (see Supplementary Table S2, available at Rheumatology online). This evidence concerns the gene TNF and adult-onset Still disease.